Plegridy

Chemical Namepeginterferon beta-1a
Dosage FormInjection (subcutaneous; 125mg/0.5mL, 63mg/0.5mL, 94mg/0.5mL)
Drug ClassModulators
SystemBlood
CompanyBiogen
Approval Year2014

Indication

  • For the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Last updated on 7/14/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Plegridy (peginterferon beta-1a) Prescribing Information.2022Biogen Inc., Cambridge, MA